Use of once-weekly semaglutide more than doubles the risk for nonarteritic anterior ischemic optic neuropathy (NAION) in individuals with type 2 diabetes, according to a study published online Dec ...

References: Cai CX, Hribar M, Baxter S, et al. Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy. JAMA Ophthalmol. 2025 Feb 20:e246555. doi:10.1001 ...

Semaglutide was associated with an increased risk for nonarteritic anterior ischemic optic neuropathy — a form of optic neuropathy that can cause blindness — in adults with type 2 diabetes or ...

HealthDay News — Semaglutide is associated with nonarteritic anterior ischemic optic neuropathy (NAION) among patients with type 2 diabetes (T2D) and those with overweight/obesity, according to ...

About The Study: The findings of this study suggest an association between semaglutide, a glucagon-like peptide 1 receptor agonist, and nonarteritic anterior ischemic optic neuropathy. As this was ...

Researchers found that among semaglutide users, the incidence rate of nonarteritic anterior ischemic optic neuropathy was 14.5 per 100,000 person-years. HealthDay News — For individuals with ...

A deep learning system achieved an accuracy of more than 90% in distinguishing arteritic from nonarteritic anterior ischemic optic neuropathy using only color fundus images, according to a study ...

Nonarteritic, Anterior Ischemic Optic Neuropathy: A Case Study Louise Lee, EdD, MHA, CHSE, PA-C ; Alison Ip, PharmD Publish Date April 28, 2021 ...

About The Study: The results of this cohort study suggest that semaglutide use was associated with an increased risk of nonarteritic anterior ischemic optic neuropathy in patients with diabetes ...